CAS 594839-88-0

General Information

Tafamidis free acid form is a non-nonsteroidal anti-inflammatory benzoxazole derivative. Tafamidis, sold under the brand name Vyndamax among others, was developed by FoldRX, now acquired by Pfizer. It was approved by FDA in 2019.

About the API

Systematic name 2-(3,5-dichlorophenyl)benzo[d]oxazole-6-carboxylic acid
Trade name(s) Vyndamax
Molecular Formula C14H7Cl2NO3
Molecular Weight 308.114
Therapeutic category Cardiovascular
Available formulations Oral Solid
Regulations US DMF Flag US DMF